FY2024 EPS Estimates for Amedisys Reduced by Leerink Partnrs

Amedisys, Inc. (NASDAQ:AMED) – Investment analysts at Leerink Partnrs cut their FY2024 earnings per share (EPS) estimates for Amedisys in a research note issued on Wednesday, January 29th. Leerink Partnrs analyst W. Mayo now expects that the health services provider will earn $4.31 per share for the year, down from their previous forecast of $4.51. The consensus estimate for Amedisys’ current full-year earnings is $4.43 per share. Leerink Partnrs also issued estimates for Amedisys’ Q4 2024 earnings at $0.96 EPS, Q1 2025 earnings at $1.20 EPS, Q2 2025 earnings at $1.50 EPS, Q3 2025 earnings at $1.17 EPS, Q4 2025 earnings at $1.04 EPS, FY2025 earnings at $4.90 EPS, Q1 2026 earnings at $1.24 EPS, Q2 2026 earnings at $1.54 EPS, Q3 2026 earnings at $1.20 EPS and Q4 2026 earnings at $1.08 EPS.

Amedisys Stock Up 0.1 %

AMED stock opened at $92.50 on Friday. The firm has a market cap of $3.03 billion, a PE ratio of 36.71, a P/E/G ratio of 1.84 and a beta of 0.72. Amedisys has a 12 month low of $82.15 and a 12 month high of $98.95. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The firm has a 50 day simple moving average of $89.41 and a 200 day simple moving average of $93.99.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, November 6th. The health services provider reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.19). The business had revenue of $587.67 million during the quarter, compared to analyst estimates of $586.75 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. Amedisys’s revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.98 earnings per share.

Institutional Investors Weigh In On Amedisys

Several large investors have recently modified their holdings of AMED. Westchester Capital Management LLC lifted its holdings in shares of Amedisys by 9.5% during the third quarter. Westchester Capital Management LLC now owns 1,118,802 shares of the health services provider’s stock valued at $107,976,000 after purchasing an additional 97,476 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Amedisys by 1.3% in the third quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock worth $54,746,000 after buying an additional 7,071 shares during the period. Pacer Advisors Inc. increased its position in shares of Amedisys by 11,621.9% in the fourth quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider’s stock worth $50,679,000 after acquiring an additional 553,435 shares in the last quarter. Calamos Advisors LLC raised its holdings in shares of Amedisys by 22.7% during the fourth quarter. Calamos Advisors LLC now owns 487,444 shares of the health services provider’s stock valued at $44,255,000 after acquiring an additional 90,097 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Amedisys by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock valued at $33,400,000 after acquiring an additional 9,004 shares in the last quarter. 94.36% of the stock is owned by institutional investors.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.